RATIONALE & OBJECTIVES: Kidney stones have been associated with increased risk for end-stage renal disease (ESRD). However, it is unclear whether there is also an increased risk for mortality and if these risks are uniform across clinically distinct categories of stone formers. STUDY DESIGN: Historical matched-cohort study. SETTING & PARTICIPANTS: Stone formers in Olmsted County, MN, between 1984 and 2012 identified using International Classification of Diseases, Ninth Revision codes. Age- and sex-matched individuals who had no codes for stones were the comparison group. PREDICTOR: Stone formers were placed into 5 mutually exclusive categories after review of medical charts: incident symptomatic kidney, recurrent symptomatic kidney, asymptomatic kidney, bladder only, and miscoded (no stone). OUTCOMES: ESRD, mortality, cardiovascular mortality, and cancer mortality. ANALYTICAL APPROACH: Cox proportional hazards models with adjustment for baseline comorbid conditions. RESULTS: Overall, 65 of 6,984 (0.93%) stone formers and 102 of 28,044 (0.36%) non-stone formers developed ESRD over a mean follow-up of 12.0 years. After adjusting for baseline hypertension, diabetes mellitus, dyslipidemia, gout, obesity, and chronic kidney disease, risk for ESRD was higher in recurrent symptomatic kidney (HR, 2.34; 95% CI, 1.08-5.07), asymptomatic kidney (HR, 3.94; 95% CI, 1.65-9.43), and miscoded (HR, 6.18; 95% CI, 2.25-16.93) stone formers, but not in incident symptomatic kidney or bladder stone formers. The adjusted risk for all-cause mortality was higher in asymptomatic kidney (HR, 1.40; 95% CI, 1.18-1.67) and bladder (HR, 1.37; 95% CI, 1.12-1.69) stone formers. Chart review of asymptomatic and miscoded stone formers suggested increased risk for adverse outcomes related to diagnoses including urinary tract infection, cancer, and musculoskeletal or gastrointestinal pain. CONCLUSIONS: The higher risk for ESRD in recurrent symptomatic compared with incident symptomatic kidney stone formers suggests that stone events are associated with kidney injury. The clinical indication for imaging in asymptomatic stone formers, the correct diagnosis in miscoded stone formers, and the cause of a bladder outlet obstruction in bladder stone formers may explain the higher risk for ESRD or death in these groups.
RATIONALE & OBJECTIVES:Kidney stones have been associated with increased risk for end-stage renal disease (ESRD). However, it is unclear whether there is also an increased risk for mortality and if these risks are uniform across clinically distinct categories of stone formers. STUDY DESIGN: Historical matched-cohort study. SETTING & PARTICIPANTS: Stone formers in Olmsted County, MN, between 1984 and 2012 identified using International Classification of Diseases, Ninth Revision codes. Age- and sex-matched individuals who had no codes for stones were the comparison group. PREDICTOR: Stone formers were placed into 5 mutually exclusive categories after review of medical charts: incident symptomatic kidney, recurrent symptomatic kidney, asymptomatic kidney, bladder only, and miscoded (no stone). OUTCOMES: ESRD, mortality, cardiovascular mortality, and cancer mortality. ANALYTICAL APPROACH: Cox proportional hazards models with adjustment for baseline comorbid conditions. RESULTS: Overall, 65 of 6,984 (0.93%) stone formers and 102 of 28,044 (0.36%) non-stone formers developed ESRD over a mean follow-up of 12.0 years. After adjusting for baseline hypertension, diabetes mellitus, dyslipidemia, gout, obesity, and chronic kidney disease, risk for ESRD was higher in recurrent symptomatic kidney (HR, 2.34; 95% CI, 1.08-5.07), asymptomatic kidney (HR, 3.94; 95% CI, 1.65-9.43), and miscoded (HR, 6.18; 95% CI, 2.25-16.93) stone formers, but not in incident symptomatic kidney or bladder stone formers. The adjusted risk for all-cause mortality was higher in asymptomatic kidney (HR, 1.40; 95% CI, 1.18-1.67) and bladder (HR, 1.37; 95% CI, 1.12-1.69) stone formers. Chart review of asymptomatic and miscoded stone formers suggested increased risk for adverse outcomes related to diagnoses including urinary tract infection, cancer, and musculoskeletal or gastrointestinal pain. CONCLUSIONS: The higher risk for ESRD in recurrent symptomatic compared with incident symptomatic kidney stone formers suggests that stone events are associated with kidney injury. The clinical indication for imaging in asymptomatic stone formers, the correct diagnosis in miscoded stone formers, and the cause of a bladder outlet obstruction in bladder stone formers may explain the higher risk for ESRD or death in these groups.
Authors: Wonngarm Kittanamongkolchai; Kristin C Mara; Ramila A Mehta; Lisa E Vaughan; Aleksandar Denic; John J Knoedler; Felicity T Enders; John C Lieske; Andrew D Rule Journal: Clin J Am Soc Nephrol Date: 2017-02-01 Impact factor: 8.237
Authors: Andrew D Rule; Veronique L Roger; L Joseph Melton; Eric J Bergstralh; Xujian Li; Patricia A Peyser; Amy E Krambeck; John C Lieske Journal: J Am Soc Nephrol Date: 2010-07-08 Impact factor: 10.121
Authors: William E Haley; Felicity T Enders; Lisa E Vaughan; Ramila A Mehta; Maxton E Thoman; Terri J Vrtiska; Amy E Krambeck; John C Lieske; Andrew D Rule Journal: Mayo Clin Proc Date: 2016-10-21 Impact factor: 7.616
Authors: R Todd Alexander; Brenda R Hemmelgarn; Natasha Wiebe; Aminu Bello; Susan Samuel; Scott W Klarenbach; Gary C Curhan; Marcello Tonelli Journal: Clin J Am Soc Nephrol Date: 2013-12-05 Impact factor: 8.237
Authors: Ziad M El-Zoghby; John C Lieske; Robert N Foley; Eric J Bergstralh; Xujian Li; L Joseph Melton; Amy E Krambeck; Andrew D Rule Journal: Clin J Am Soc Nephrol Date: 2012-06-28 Impact factor: 8.237
Authors: Wonngarm Kittanamongkolchai; Lisa E Vaughan; Felicity T Enders; Tsering Dhondup; Ramila A Mehta; Amy E Krambeck; Cynthia H McCollough; Terri J Vrtiska; John C Lieske; Andrew D Rule Journal: Mayo Clin Proc Date: 2018-02-14 Impact factor: 7.616
Authors: W Cheungpasitporn; C Thongprayoon; O A O'Corragain; P J Edmonds; P Ungprasert; W Kittanamongkolchai; S B Erickson Journal: QJM Date: 2014-09-09
Authors: Wilson Sui; Josh K Calvert; Nicholas L Kavoussi; Edward R Gould; Nicole L Miller; Cosmin A Bejan; Ryan S Hsi Journal: J Endourol Date: 2020-07-27 Impact factor: 2.942
Authors: Ryan S Hsi; Phyllis L Yan; David S Goldfarb; Ada Egbuji; Yajuan Si; Vahakn Shahinian; John M Hollingsworth Journal: Urology Date: 2020-12-19 Impact factor: 2.649
Authors: Anna L Zisman; Fredric L Coe; Andrew J Cohen; Christopher B Riedinger; Elaine M Worcester Journal: Clin J Am Soc Nephrol Date: 2020-06-19 Impact factor: 8.237